SecBot SecBot
8-K ·Filed Jul 1, 2026

SEM

SELECT MEDICAL HOLDINGS CORP
BULLISH
Impact 8/10
Horizonimmediate Processed4mo ago SEC0001104659-26-079643
Killer combo: M&A completed + management change
Actionable Insight ▲ Bullish

The take-private is complete. SEM shares will cease trading on the NYSE and will be deregistered. Traders holding SEM should have already tendered shares for the $16.50 cash consideration. No further trading action is possible in the public market. Monitor for any appraisal rights litigation or post-closing adjustments, but the primary event is concluded.

DirectionBullish
Confidencehigh
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Select Medical Holdings Corporation (SEM) was acquired by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe (WCAS) in a take-private transaction that closed on June 30, 2026. Shareholders received $16.50 per share in cash, representing an ~18% premium to the unaffected price. The company simultaneously entered into a $1 billion incremental term loan facility to help finance the acquisition. As a result, SEM common stock is being delisted from the NYSE and will be deregistered, with the company becoming a wholly-owned indirect subsidiary of the acquirer.

Key Financial Metrics

Deal Value
$3.9B
Premium
18%
Deal Type
merger

Key Facts

  • Merger closed on June 30, 2026, effective July 1, 2026 at 12:01 a.m.
  • Shareholders received $16.50 per share in cash, valuing the company at approximately $3.9 billion.
  • The purchase price represents an ~18% premium over the unaffected share price of $13.98 (Nov 24, 2025) and ~25% over the 90-day VWAP.
  • Aggregate purchase price paid for all outstanding shares was approximately $1.7 billion.
  • A new $1,000,000,000 Tranche B-3 Term Loan facility was established under the existing credit agreement to fund the acquisition.
  • WCAS XIV, L.P. and other investors contributed at least 25% of the total consideration as equity.
  • SEM common stock is being delisted from the NYSE and the company will file a Form 15 to suspend SEC reporting obligations.
  • Seven directors (William H. Frist, Daniel J. Thomas, Katherine R. Davisson, Parvinderjit S. Khanuja, James S. Ely III, Thomas A. Scully, Marilyn B. Tavenner) resigned; Russell L. Carson, David S. Chernow, and Robert A. Ortenzio now serve as directors.
  • Current officers, including Robert A. Ortenzio and Martin F. Jackson, will continue to lead the business.
  • The company's certificate of incorporation and bylaws were amended and restated.

Financial Impact

Shareholders received $16.50 per share in cash, a total equity value of approximately $1.7 billion for the public float. The enterprise value is approximately $3.9 billion. A new $1 billion term loan was added to the company's debt structure.

share priceenterprise valuedebtownership structure

Risk Factors

  • Potential appraisal rights litigation from shareholders who dissented and demand fair value above $16.50.
  • Integration risk for the newly leveraged company under private equity ownership.
  • No further public market liquidity for SEM shares.

Market Snapshot

Exchange
NYSE
Sector
Services-Hospitals
Analyst Consensus
0% bullish (12 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-079643
Document: tm2619266d7_ex3-2.htm0001104659-26-079643
Document: tm2619266d7_8k.htm0001104659-26-079643
Document: tm2619266d7_ex3-1.htm0001104659-26-079643
Document: tm2619266d7_ex99-1.htm0001104659-26-079643
Document: 0001104659-26-079643-index-headers.html0001104659-26-079643
Document: 0001104659-26-079643-index.html0001104659-26-079643
Document: 0001104659-26-079643.txt0001104659-26-079643

Track record

8 reports on SEM

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +1.54% at T+60 after the Mar 3, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Jul 13, 202618w ago 15-12G Neutral 4/10 No price data
  2. Jul 1, 202619w ago 25-NSE Neutral 9/10 Entry $16.52 No price data
  3. Jul 1, 202619w ago 8-K Bullish 8/10 Viewing Entry $16.52 No price data
  4. Jun 26, 202620w ago 8-K Bullish 7/10 Entry $16.53 No price data
  5. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $16.38 to $16.51 ▼ −0.81% +4.45% vs SPY
  6. Apr 15, 202630w ago PREM14A Bullish 8/10 Entry $16.38 to $16.45 ▲ +0.43% −5.62% vs SPY
  7. Mar 4, 202636w ago DEFA14A Neutral 3/10 Entry $16.25 to $16.29 ▲ +0.25% +4.66% vs SPY
  8. Mar 3, 202636w ago DEFA14A Bullish 9/10 Entry $16.26 to $16.29 ▲ +0.18% +4.59% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 8h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 1, 2026